http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
-
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
-
Athira Pharma Inc. (ATHA) Responds to Richard A. Kayne’s Suspension of His Proxy Contest
-
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
-
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
-
Athira Pharma Inc. (ATHA) Reports Preclinical Data
-
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
-
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
-
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
-
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
-
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
-
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
-
Athira Pharma Inc. (ATHA) Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
-
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
-
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
-
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees
-
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees
-
Athira Pharma Inc. (ATHA) Issues Letter to Shareholders
-
Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
-
Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
-
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card
-
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card
-
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
-
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
-
Athira Pharma Inc. (ATHA) Mails Shareholder Letter Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
-
Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
-
Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
-
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders
-
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders
-
Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions
-
Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions
-
Athira Pharma Inc. (ATHA) Highlights Strong Execution of Strategy and Positioning for the Future
-
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future
-
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future
-
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
-
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
-
Athira Pharma Inc. (ATHA) Appoints Michael A. Panzara to its Board
-
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
-
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
-
Athira Pharma to Participate in Two Upcoming Investor Conferences
-
Athira Pharma to Participate in Two Upcoming Investor Conferences
-
Athira Pharma Inc. (ATHA) Reports Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
-
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
-
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
-
Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022
-
Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022
-
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress
-
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress
-
Athira Pharma (ATHA) Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at ASENT
-
Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
